Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy of Dermatology Annual Meeting.

oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy of Dermatology Annual Meeting.

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting showed that the candidate, icotrokinra (JNJ-2113), was associated with ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...